REGENT PACIFIC(00575): Deep Longevity strategically entered the US market in the first quarter of 2026.

REGENT PACIFIC (00575) announced that Deep Longevity, Inc., a global leader in explainable artificial intelligence driving the aging clock and longevity science, and its affiliated companies (referred to as Deep Longevity) will launch an expansion plan into the United States in the first quarter of 2026. This move will place Deep Longevity at the core of the world's largest and fastest-growing health market, currently valued at over $6.8 trillion. The United States demonstrates unparalleled scale and demand for evidence-based longevity solutions. Deep Longevity's clinically validated deep aging clocks - including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge - provide precise and multidimensional biological age assessments that far surpass chronological age. These tools empower consumers, doctors, employers, and insurance companies with actionable and personalized insights to extend healthy lifespans and slow down aging. To drive rapid adoption, Deep Longevity is establishing a domestic sales team in the United States, with the first two sales personnel set to join on January 1, 2026. The new team will establish high-impact partnerships with longevity platforms, consumer health applications, diagnostic laboratories, health clinics, corporate health programs, insurance companies, employers, and high-end health service providers. Initially, the team will focus sales efforts on the southeastern United States, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia. Deepankar Nayak, CEO of Deep Longevity, said, "Entering the United States is a significant milestone in Deep Longevity's development journey. Our aging clocks have gained trust from leading clinics and platforms worldwide. With a dedicated U.S. team, we are ready to bring personalized preventive longevity care to millions of people and capture a significant share of this $6.8 trillion opportunity." Deep Longevity's technology is supported by dozens of peer-reviewed papers and multiple granted patents. Their multimodal aging clocks integrate blood biomarkers, epigenetics, psychology, biology, and integrated facial imaging to provide the most comprehensive biological aging profile available today. Deep Longevity, Inc. (a wholly-owned subsidiary of the company) along with its affiliated companies, have developed an explainable artificial intelligence system tracking human aging at the molecular, cellular, organ, and psychological levels. Deep Longevity's patented deep aging clocks provide vertical Software as a Service (SaaS) solutions for consumers, doctors, and businesses, offering personalized recommendations that are proven to improve health conditions and extend healthy lifespans.